Tirzepatide versus Semaglutide effects on blood sugar and weight in people with type 2 diabetes

Declarations. Conflict of Interest: Meredith M. Hoog, Carlos Vallarino, Juan M. Maldonado, and Kendra Terrell are employees and stockholders of Eli Lilly and Company. Michael Grabner, Chia-Chen Teng, and Emma L. Richard are employees of Carelon Research, which received funding from Eli Lilly and Company for the conduct of this study as well as for manuscript writing. Michael Grabner, Chia-Chen Teng, and Emma L. Richardare stockholders of Elevance Health. Ethical Approval: Researchers accessed data in the format of a limited data set for which data use agreements were in place with the covered entities in compliance with the Health Insurance Portability and Accountability Act Privacy Rule. An Institutional Review Board did not review the study since only this limited data set was accessed. As this observational study used previously collected data and did not impose any intervention, the data were de-identified to protect participant privacy. Therefore, a formal Consent to Release Information form was not required. The study was conducted according to the ethical principles that originate in the Declaration of Helsinki and are consistent with Good Pharmacoepidemiology Practices and applicable laws and regulations in the US.